论文部分内容阅读
目的观察阿托伐他汀治疗心肌梗死后无症状心力衰竭患者的临床疗效。方法将2014年3月-2015年3月收治医院的心肌梗死后无症状心力衰竭患者84例,随机分为观察组和对照组各42例,对照组采取常规治疗方法,观察组在常规治疗的基础上采取阿托伐他汀进行治疗,对2组临床治疗效果进行对比评价。结果 (1)治疗前,2组在血浆B型钠尿肽(NT-pro BNP)水平方面比较差异无统计学意义(P>0.05);治疗后,2组NT-pro BNP水平均有所改善,且观察组改善较对照组明显(P<0.05)。(2)治疗后,2组左室射血分数(LVEF)、左室收缩末期内径(LVDS)较治疗前明显改善,且观察组改善较对照组明显,差异有统计学意义(P<0.05)。治疗前后左室舒张末期内径(LVDD)无明显变化。(3)观察组治疗前6min步行距离为(248.2±35.6)m、治疗后为(268.4±48.6)m;对照组患者,治疗前6min步行距离为(248.5±35.8)m、治疗后为(254.2±48.3)m。治疗前,2组患者6min步行距离无明显差异(P>0.05);治疗后,观察组患者6min步行距离明显多于对照组,差异均有统计学意义(P<0.05)。结论心肌梗死后无症状心力衰竭患者应用阿托伐他汀治疗效果显著,患者的NT-pro BNP水平能够得到有效改善,同时使患者的心功能得到有效改善,进而改善患者生存质量;因此,值得在临床中采纳及应用。
Objective To observe the clinical efficacy of atorvastatin in patients with asymptomatic heart failure after myocardial infarction. Methods From March 2014 to March 2015, 84 patients with asymptomatic heart failure after hospitalization for myocardial infarction in our hospital were randomly divided into observation group (42 cases) and control group (42 cases). The control group was treated by conventional therapy and the control group On the basis of atorvastatin treatment, the clinical efficacy of two groups were evaluated. Results (1) There was no significant difference in plasma NT-pro BNP levels between the two groups before treatment (P> 0.05). After treatment, the levels of NT-pro BNP in both groups were improved , And the improvement of observation group than the control group (P <0.05). (2) After treatment, LVEF and LVDS in two groups were significantly improved compared with that before treatment, and the improvement in observation group was more significant than that in control group (P <0.05) . Before and after treatment, left ventricular end-diastolic diameter (LVDD) had no significant change. (3) In the observation group, walking distance was (248.2 ± 35.6) m at 6 min before treatment and (268.4 ± 48.6) m after treatment; in the control group, walking distance at 6 min before treatment was (248.5 ± 35.8) m, ± 48.3) m. Before treatment, there was no significant difference in walking distance between the two groups at 6min (P> 0.05). After treatment, the walking distance of patients in the observation group was significantly more than that of the control group at 6min, the difference was statistically significant (P <0.05). Conclusions Atorvastatin is effective in patients with asymptomatic heart failure after myocardial infarction. NT-pro BNP level can be effectively improved in patients with myocardial infarction. At the same time, the patient’s cardiac function can be effectively improved, thereby improving the quality of life of patients. Therefore, Clinical adoption and application.